Novartis AG Total Liabilities

The latest total liabilities for NVS is $80B as of June 2026. That compares with $62B in the prior-year period — up 28.2% year over year. Investors often review this figure alongside Novartis AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVS's total liabilities moved from $62B to $80B — a 28.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novartis AG's operating scale or balance-sheet position.

A total liabilities figure of $80B for NVS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVS's total liabilities ($80B), review year-over-year change from $62B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Novartis AG's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.